Synthesis of CuS@MSN@SpAcDex for Tacrolimus delivery to treat End Stage Renal Disease
Shrestha, Brajesh (2021)
Shrestha, Brajesh
2021
All rights reserved. This publication is copyrighted. You may download, display and print it for Your own personal use. Commercial use is prohibited.
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi-fe2021070541161
https://urn.fi/URN:NBN:fi-fe2021070541161
Tiivistelmä
The treatment of End stage renal disease (ESRD) is kidney transplantation. In order to keep the transplanted kidney safe in the patient’s body, it is necessary to kill the patient’s immune cells present in the endothelial cells. Although the use of tacrolimus and methylprednisolone drugs was found to be effective in killing patient's immune cells, the traditional oral administration makes these drugs not fully effective because of their poor water solubility and less absorption by the gastrointestinal tract. Thus, an improved therapy such as a drug delivery method is needed, where the complete dose of these drugs, with the help of nanoparticles, will reach the target site and kill the immune cells. Nanoparticles such as MSN and CuS@MSN can load tacrolimus and methylprednisolone, respectively, and deliver them to the target site.
In the present study, the MSN and CuS@MSN were synthesized in the laboratory using an easy and inexpensive method that gives a significant amount of good nanoparticles. The size of MSN and CuS@MSN were ranged from 50-80 nm and 50-120 nm, respectively. In addition, the MSN was loaded with tacrolimus, and the loading efficiency was found to be significantly high (approximately 63%) after the use of MSN and tacrolimus in a 1:5 ratio. In addition, the tacrolimus-loaded MSN was further encapsulated with SpAcDex polymer to form the MSN-tacrolimus-SpAcDex complex for further stability. Furthermore, the zeta potentials of MSN alone and MSN-tacrolimus were measured, and they were -19.1 mV and -19.5 mV.
These MSN and MSN-tacrolimus-SpAcDex were treated with HUVECs for 2 hours, with the help of WST-1 assay, in order to determine the in vitro cell viability and cytotoxicity. The WST-1 assay was found to be precise, sensitive, reliable, inexpensive, and fast. The assay showed that both nanoparticles and nanoparticle complexes do not pose any cytotoxicity and do not inhibit the growth of HUVECs. In addition, they are biocompatible. Furthermore, the cellular uptake of these nanoparticle complexes was confirmed after the result of confocal microscopy. Thus, MSN and MSN-tacrolimus-SpAcDex complex can act as a good vehicle for drug delivery methods.
In the present study, the MSN and CuS@MSN were synthesized in the laboratory using an easy and inexpensive method that gives a significant amount of good nanoparticles. The size of MSN and CuS@MSN were ranged from 50-80 nm and 50-120 nm, respectively. In addition, the MSN was loaded with tacrolimus, and the loading efficiency was found to be significantly high (approximately 63%) after the use of MSN and tacrolimus in a 1:5 ratio. In addition, the tacrolimus-loaded MSN was further encapsulated with SpAcDex polymer to form the MSN-tacrolimus-SpAcDex complex for further stability. Furthermore, the zeta potentials of MSN alone and MSN-tacrolimus were measured, and they were -19.1 mV and -19.5 mV.
These MSN and MSN-tacrolimus-SpAcDex were treated with HUVECs for 2 hours, with the help of WST-1 assay, in order to determine the in vitro cell viability and cytotoxicity. The WST-1 assay was found to be precise, sensitive, reliable, inexpensive, and fast. The assay showed that both nanoparticles and nanoparticle complexes do not pose any cytotoxicity and do not inhibit the growth of HUVECs. In addition, they are biocompatible. Furthermore, the cellular uptake of these nanoparticle complexes was confirmed after the result of confocal microscopy. Thus, MSN and MSN-tacrolimus-SpAcDex complex can act as a good vehicle for drug delivery methods.
Kokoelmat
- 3111 Biolääketieteet [11]